Literature DB >> 20880390

Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action.

Georges Vauquelin1, Steven J Charlton.   

Abstract

An increasing number of examples in the literature suggest that the in vivo duration of drug action not only depends on macroscopic pharmacokinetic properties like plasma half-life and the time needed to equilibrate between the plasma and the effect compartments, but is also influenced by long-lasting target binding and rebinding. The present review combines information from different research areas and simulations to explore the nature of these mechanisms and the conditions in which they are most prevalent. Simulations reveal that these latter phenomena become especially influential when there is no longer sufficient free drug around to maintain high levels of receptor occupancy. There is not always a direct link between slow dissociation and long-lasting in vivo target protection, as the rate of free drug elimination from the effect compartment is also a key influencing factor. Local phenomena that hinder the diffusion of free drug molecules away from their target may allow them to consecutively bind to the same target and/or targets nearby (denoted as 'rebinding') even when their concentration in the bulk phase has already dropped to insignificant levels. The micro-anatomic properties of many effect compartments are likely to intensify this phenomenon. By mimicking the complexity of tissues, intact cells offer the opportunity to investigate both mechanisms under the same, physiologically relevant conditions.

Mesh:

Substances:

Year:  2010        PMID: 20880390      PMCID: PMC2990149          DOI: 10.1111/j.1476-5381.2010.00936.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  132 in total

Review 1.  Models and methods for studying insurmountable antagonism.

Authors:  Georges Vauquelin; Isabelle Van Liefde; Patrick Vanderheyden
Journal:  Trends Pharmacol Sci       Date:  2002-11       Impact factor: 14.819

Review 2.  Advanced pharmacokinetic models based on organ clearance, circulatory, and fractal concepts.

Authors:  K Sandy Pang; Michael Weiss; Panos Macheras
Journal:  AAPS J       Date:  2007-06-29       Impact factor: 4.009

Review 3.  Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane.

Authors:  T Okamoto; A Schlegel; P E Scherer; M P Lisanti
Journal:  J Biol Chem       Date:  1998-03-06       Impact factor: 5.157

4.  Approximating the effects of diffusion on reversible reactions at the cell surface: ligand-receptor kinetics.

Authors:  B Goldstein; M Dembo
Journal:  Biophys J       Date:  1995-04       Impact factor: 4.033

5.  Flow-enhanced adhesion regulated by a selectin interdomain hinge.

Authors:  Jizhong Lou; Tadayuki Yago; Arkadiusz G Klopocki; Padmaja Mehta; Wei Chen; Veronika I Zarnitsyna; Nicolai V Bovin; Cheng Zhu; Rodger P McEver
Journal:  J Cell Biol       Date:  2006-09-25       Impact factor: 10.539

6.  Neurokinin 1 receptor antagonists: correlation between in vitro receptor interaction and in vivo efficacy.

Authors:  Erik Lindström; Bengt von Mentzer; Ingrid Påhlman; Ingela Ahlstedt; Anna Uvebrant; Elin Kristensson; Rakel Martinsson; Anna Novén; Jennie de Verdier; Georges Vauquelin
Journal:  J Pharmacol Exp Ther       Date:  2007-06-15       Impact factor: 4.030

Review 7.  Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator.

Authors:  G P Anderson
Journal:  Life Sci       Date:  1993       Impact factor: 5.037

8.  Interleukin-8 in airway inflammation in patients with asthma and chronic obstructive pulmonary disease.

Authors:  R E Nocker; D F Schoonbrood; E A van de Graaf; C E Hack; R Lutter; H M Jansen; T A Out
Journal:  Int Arch Allergy Immunol       Date:  1996-02       Impact factor: 2.749

9.  Peripheral 5-HT2-like receptors. Can they be classified with the available antagonists?

Authors:  P Leff; G R Martin
Journal:  Br J Pharmacol       Date:  1986-07       Impact factor: 8.739

10.  Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells.

Authors:  D D Taub; A R Lloyd; K Conlon; J M Wang; J R Ortaldo; A Harada; K Matsushima; D J Kelvin; J J Oppenheim
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

View more
  73 in total

1.  Functional efficacy of adenosine A₂A receptor agonists is positively correlated to their receptor residence time.

Authors:  Dong Guo; Thea Mulder-Krieger; Adriaan P IJzerman; Laura H Heitman
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 2.  The drug-target residence time model: a 10-year retrospective.

Authors:  Robert A Copeland
Journal:  Nat Rev Drug Discov       Date:  2015-12-18       Impact factor: 84.694

Review 3.  On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets.

Authors:  Georges Vauquelin; Isabelle Van Liefde; David C Swinney
Journal:  Br J Pharmacol       Date:  2016-03-15       Impact factor: 8.739

Review 4.  G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.

Authors:  Stacy Gelhaus Wendell; Hao Fan; Cheng Zhang
Journal:  Pharmacol Rev       Date:  2020-01       Impact factor: 25.468

5.  Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time.

Authors:  Georges Vauquelin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-06-28       Impact factor: 3.000

Review 6.  [Medicine from the computer].

Authors:  K Andrae; V Durmaz; K Fackeldey; O Scharkoi; M Weber
Journal:  Anaesthesist       Date:  2013-07       Impact factor: 1.041

7.  [Medicine from the computer].

Authors:  K Andrae; V Durmaz; K Fackeldey; O Scharkoi; M Weber
Journal:  Schmerz       Date:  2013-08       Impact factor: 1.107

8.  [Medicine from the computer].

Authors:  K Andrae; V Durmaz; K Fackeldey; O Scharkoi; M Weber
Journal:  Z Rheumatol       Date:  2013-10       Impact factor: 1.372

9.  Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting β2-adrenoceptor agonists.

Authors:  David A Sykes; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

10.  Picomolar Affinity Antagonist and Sustained Signaling Agonist Peptide Ligands for the Adrenomedullin and Calcitonin Gene-Related Peptide Receptors.

Authors:  Jason M Booe; Margaret L Warner; Augen A Pioszak
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.